Braden Michael Leonard, a major shareholder in Aclaris Therapeutics, Inc. (NASDAQ:ACRS), recently acquired 150,000 shares of the company’s stock in a transaction that took place on Monday, June 17th. The shares were purchased at an average price of $1.13 each, totaling $169,500.00. With this purchase, Leonard now holds 11,502,134 shares of Aclaris Therapeutics, valued at $12,997,411.42. This transaction was disclosed in a filing with the SEC, which can be accessed on the SEC website.
In addition to this recent purchase, Braden Michael Leonard also made two other significant trades earlier in June. On Thursday, June 13th, Leonard bought 528,621 shares of Aclaris Therapeutics at $1.15 per share, totaling $607,914.15. Prior to that, on Tuesday, June 11th, Leonard acquired 1,000,000 shares at an average price of $1.08, amounting to $1,080,000.00.
Aclaris Therapeutics’ stock performance has been relatively stable, with shares remaining flat at $1.13 during recent trading hours. The company has a market capitalization of $80.52 million, a PE ratio of -1.04, and a beta of 0.06. The firm’s 50-day simple moving average is $1.17, while its 200-day simple moving average is $1.16.
In terms of earnings, Aclaris Therapeutics reported earnings per share of ($0.24) for the last quarter, surpassing the consensus estimate of ($0.28) by $0.04. The company had a revenue of $2.40 million for the quarter, exceeding analysts’ expectations. Looking ahead, analysts project that Aclaris Therapeutics, Inc. will post -0.81 earnings per share for the current year.
Several institutional investors have recently adjusted their holdings of Aclaris Therapeutics. For example, BML Capital Management LLC acquired a new position in the company’s shares, Vanguard Group Inc. increased its holdings, and other firms like Trexquant Investment LP and Monaco Asset Management SAM also invested in Aclaris Therapeutics.
Stock analysts have provided various ratings for Aclaris Therapeutics, with some downgrading the stock while others maintain a hold or buy recommendation. The consensus price target for the company is $22.25.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drug candidates for immune-inflammatory diseases in the United States. The company operates in two segments, Therapeutics, and Contract Research, aiming to address significant unmet needs in immuno-inflammatory diseases.
In conclusion, while major shareholder Braden Michael Leonard’s recent acquisitions of Aclaris Therapeutics shares indicate confidence in the company, it’s essential for investors to conduct thorough research and consider various factors before making investment decisions. Additional information like institutional investments and analyst ratings can provide valuable insights for potential investors looking to explore opportunities in the biopharmaceutical sector.
